The global kinase inhibitor in autoimmune diseases market is expected to be valued at USD 47,430 Million in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to USD 80,252 Million by 2033.
The increasing healthcare spending and increasing awareness pertaining to autoimmune diseases are likely to drive the growth of the kinase inhibitor in the autoimmune diseases market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 47,430 Million |
| Projected Forecast Value (2033) | USD 80,252 Million |
| Global Growth Rate (2023 to 2033) | 5.4% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The kinase inhibitor in the autoimmune diseases market is expected to gain market growth in the forecast period of 2023 to 2033. Latest market analysis by FMI the market is to grow at a CAGR of 5.4% in the above-mentioned forecast period.
Autoimmune diseases occur when the immune system attacks one or more cells of the body which are functioning normally owing to the irregularities. The mis-functioning of the immune system is a result of the failure to recognize immune cells, tissues, and organs and produce autoantibodies targeting these cells.
There are massive technological developments happening in the healthcare sector, especially in the area of autoimmune disease treatment. Companies are making use of this technology to develop much more evolved forms of tyrosine kinase inhibitors. This might increase the demand for kinase inhibitors for cancer treatment during the forecast period. Presently, pharmaceutical companies are investing heavily in Research and Development to develop enhanced kinase inhibitors. This is currently driving the market growth. The global kinase inhibitor in the autoimmune diseases market rose at a CAGR of 5.1% from 2018 to 2022.
Growing Healthcare Spending to Drive the Kinase Inhibitor in Autoimmune Disease Market
The increasing prevalence of autoimmune and chronic diseases including rheumatic arthritis, psoriatic arthritis, ulcerative colitis, etc. is expected to drive the growth of kinase inhibitors in the autoimmune disease market.
Additionally, the increasing number of special designations for drugs in the pipeline is also expected to fuel the growth of the market. Kinase Inhibitor in the autoimmune disease market is primarily driven by a few key factors such as the rising prevalence of autoimmune disease, patient awareness regarding rising healthcare concerns, increase in healthcare expenditure.
The considerable efforts by the governments as well as the private players across the world in improving, rebuilding, and innovating healthcare infrastructure across the globe are also translating into various worthwhile development opportunities for the players in the global kinase inhibitor autoimmune diseases market in coming years. Rising government initiatives and the increase in automation technologies lead to higher sensitivity, faster and easy performing diagnosis test results, and prevention of disease.
Increased Research and Development Drive the Market During the Forecast Period
The rising prevalence of autoimmune diseases is likely to fuel the growth of the kinase inhibitor in the autoimmune disease market. Therefore, a consistent increase in the autoimmune patient population across the world has been identified as one of the major factors driving the kinase inhibitor in the autoimmune disease market.
The pharmaceutical companies on Research and Development to come up with potential kinase inhibitors for the treatment of autoimmune diseases are driving the growth of kinase inhibitors in the autoimmune disease market, globally. More than 400 diseases have been associated directly or indirectly with protein kinase. The success of kinase inhibitors in treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis has showcased their therapeutic potential. This success, coupled with a greater understanding of inflammatory signaling cascades, led to kinase inhibitors taking center stage to pursue new anti-inflammatory agents for the treatment of immune-mediated diseases.
The expected launch of emerging therapies such as SHR0302, Ruxolitinib, Branebrutinib, Ritlecitinib, Ritlecitinib/PF-06650833/ Tofacitinib, Abrocitinib, PF-06826647, Brepocitinib, SHR0302, Ruxolitinib, Branebrutinib likely to drive the market during the forecast period.
Principal Consultant
Lack of Skilled Professional May Hamper the Market Growth
The high cost associated with the latest clinical trials and complex approvals processes is acting as a major obstruction to the growth of kinase inhibitors in the autoimmune diseases market. On the other hand, the dearth of skilled professionals and technicians as well as the rise in the lack of understanding about the basic aetiology of autoimmune disorders may restrict the growth in the global kinase inhibitor autoimmune diseases market in near future.
However, modernization, as well as technological advancements in medical and healthcare devices as well as the constant efforts by the industry players on geographical as well as product offerings expansion, are anticipated to bolster the rising demand in the global kinase inhibitor in autoimmune diseases market over the forecast period.
Increasing Rate of Autoimmune Diseases in the USA to Propel the Market Growth
The USA is estimated to account for over 5.2% of the North American market in 2022. The growth of the market in the region is attributed to the increasing prevalence of autoimmune diseases. North America holds a leading position in the Kinase inhibitor in the autoimmune disease Market due to the growing incidence of autoimmune disorders such as rheumatoid arthritis, and diabetes type I in the region.
According to the National Institutes of Health, up to 23.5 million Americans (more than seven percent of the population) suffer from an autoimmune disease - and the prevalence is rising.
Government initiatives such as the Affordable Care Act and Patient Protection Act are further fueling the growth of the market size of kinase inhibitors in autoimmune diseases.
Rising Investments in Research and Development Driving Growth in Europe Market
The Europe kinase inhibitors in the autoimmune disease market are expected to rise at a CAGR of 5.1% from 2023 to 2033. Europe is expected to have the second-largest market for global kinase inhibitors in the autoimmune disease market. Increasing awareness among people about diseases is also a major factor that may boost the growth of the market in this region.
The growing advancement of healthcare infrastructure, increasing per-capita income, and MNCs strengthening their distribution network all these factors also boost the market growth. Increased penetration of new technologies such as potable diagnostic equipment and novel biomarkers are contributing largely to the market growth of Europe.
Rapid development in pharmaceuticals to drive the market growth in Asia Pacific
Asia Pacific is anticipated to experience the fastest growth in the kinase inhibitors in the autoimmune diseases market as a result of an increase in the prevalence of chronic diseases, and autoimmune diseases. Asia is expected to be the fastest-growing market in the upcoming years. This is due to the rising aging population and improving healthcare infrastructure in this region. Moreover, rising awareness about better healthcare facilities is also driving the growth of the autoimmune disease treatment market in the region.
Rising awareness about healthcare and increasing investments in Research and Development in pharmaceutical and life sciences sectors are some of the key factors driving the growth of the global kinase inhibitor in the autoimmune diseases market. However, in the Middle East and Africa market growth is expected to be limited due to slow economic growth, underdeveloped infrastructure, and lower access to technological advancement.
| UK | 5.1% |
|---|---|
| India | 4.8% |
| South Korea | 4.9% |
| China | 5.0% |
| USA | 5.2% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Anti-inflammatory Drugs Segment remains dominant among other Drugs Types
Anti-inflammatory Drugs (NSAIDs) dominated the industry in 2023. The anti-inflammatory segment dominated the global market in 2023 with a revenue share of over 45.3%. This is attributed to the high level of penetration of drugs, and availability at lower cost in comparison to drugs of other classes.
Some of the drugs to treat autoimmune diseases include NSAID, DMARD, biologic DMARD, and 5-ASA. Other therapies such as bridge therapy, topical therapy, phototherapy, and recombinant technology are also used for the treatment of these diseases. On the other hand, corticosteroids anticipated to witness the fastest growth over the forecast period are typically used to treat rheumatologic diseases, like rheumatoid arthritis, lupus, or vasculitis.
How do New Entrants Contribute to the Kinase Inhibitor in Autoimmune Diseases Market?
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the kinase inhibitor in the autoimmune diseases market.
Some of the start-ups in the kinase inhibitor in autoimmune diseases market include-
The professional survey study carefully analyses the operations and overview of the corporate structures and functioning of the leading and major manufacturers and players functional within the global kinase inhibitor in the autoimmune diseases market. It assesses its product offerings, financial outlook, sales, revenue, and growth over the forecast period.
Some of the leading manufacturers and players assessed in the global kinase inhibitor in autoimmune treatment market include Pfizer, Reistone Biopharma, Eli Lily and Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Incyte Corporation, Bristol Myers Squibb, Galapagos NV, and others
Manufacturers and players functional in the global kinase inhibitor in autoimmune diseases market are adopting various corporate growth strategies such as new product launches, mergers and acquisitions, and geographical expansion, among others.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR from 2023 to 2033 |
| Expected Market Value (2023) | USD 47,430 Million |
| Projected Forecast Value (2033) | USD 80,252 Million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Treatment, Drug, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand |
| Key Companies Profiled | Pfizer; Reistone Biopharma; Eli Lily and Company; AbbVie; Gilead Sciences; Astellas Pharma; Japan Tobacco and Torii Pharmaceutical; Incyte Corporation; Bristol Myers Squibb; Galapagos NV |
| Customization | Available Upon Request |
The global kinase inhibitor in autoimmune diseases market is likely to reach a valuation of USD 47,430 Million by the end of 2023.
Pfizer, Reistone Biopharma, Eli Lily and Incyte Corporation, AbbVie, Gilead Sciences, Astellas Pharma are some of the key players in the global kinase inhibitor in autoimmune diseases market
Sales of the kinase inhibitor in autoimmune diseases market are likely to expand at 5.4% CAGR through 2033
The USA, Canada, Japan, China, & Germany are expected to drive most of the demand for kinase inhibitor in autoimmune diseases market
By the end of 2033, the global market for kinase inhibitor in autoimmune diseases market is predicted to reach a valuation of USD 80,252 Million
1. Executive Summary | Kinase Inhibitor in Autoimmune Diseases Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Physical Therapy 5.2. Treatment for Deficiency 5.3. Surgery 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug 6.1. Anti-inflammatory Drugs 6.2. Corticosteroids 6.3. Pain-killing Medications 6.4. Immunosuppressants 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. Middle East and Africa (MEA) 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Pfizer 15.2. Reistone Biopharma 15.3. Eli Lily and Incyte Corporation 15.4. AbbVie 15.5. Gilead Sciences 15.6. Astellas Pharma 15.7. Japan Tobacco and Torii Pharmaceutical 15.8. Incyte Corporation 15.9. Bristol Myers Squibb 15.10. Galapagos NV 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Kinase Inhibitor in Autoimmune Diseases Market
